✦ LIBER ✦

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

✍ Scribed by Kenneth H Fife; Cosette M Wheeler; Laura A Koutsky; Eliav Barr; Darron R Brown; Melissa A Schiff; Nancy B Kiviat; Kathrin U Jansen; Harriet Barber; Judith F Smith; Amha Tadesse; Katherine Giacoletti; Paula R Smith; Gretchen Suhr; Daniel A Johnson

Book ID: 116957121
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 146 KB
Volume: 22
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2003.11.058

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, immunogenicity, and efficacy of

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

✍ Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. Garc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naï

Comparison of the Immunogenicity and Rea

Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women

✍ Block, S. L.; Nolan, T.; Sattler, C.; Barr, E.; Giacoletti, K. E.D.; Marchant, C 📂 Article 📅 2006 🏛 American Academy of Pediatrics 🌐 English ⚖ 409 KB

The impact of a quadrivalent human papil

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24

✍ S Majewski; FX Bosch; J. Dillner; O-E Iversen; SK Kjaer; N Muñoz; S-E Olsson; J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

Immunogenicity of a Prophylactic Quadriv

Immunogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescent Transplant Recipients

✍ Gomez-Lobo, V.; Moudgil, A.; Whyte, T.; Kaufman, S.; Torres, C.; Mete, M. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Priming of Human Papillomavirus Type 11-

Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine

✍ Emeny, R. T.; Wheeler, C. M.; Jansen, K. U.; Hunt, W. C.; Fu, T.-M.; Smith, J. F 📂 Article 📅 2002 🏛 American Society for Microbiology 🌐 English ⚖ 991 KB

Efficacy of a bivalent L1 virus-like par

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

✍ Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 185 KB